LANOXICAPS
LOE ApproachingNDAORALCAPSULE
Approved
Jul 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LANOXICAPS is an oral capsule formulation of a small-molecule cardiac glycoside approved in 1982 by GSK. The drug mechanism of action and specific indications are not documented in available records. The product is currently in late-stage lifecycle with loss of exclusivity approaching.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial team is likely focused on transition planning and generic defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current job openings are linked to LANOXICAPS, reflecting its mature lifecycle status and minimal staffing growth. Career opportunities on this product are limited and primarily defensive in nature, focusing on generic transition and patient retention rather than expansion.
Brand ManagerSales Representative
Worked on LANOXICAPS at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.